Abstract:CAR T-cells have shown great potential for the future of cancer immunotherapy after showing promising clinical results in treating several hematologic tumors. Despite these early successes, several challenges remain in the field. One such challenge is a lack of long-term persistence of CD28-based CAR T-cells in patients. Although CD28-based CAR T-cells mount a robust acute tumor killing response, they are more prone to early exhaustion, terminal differentiation and cell death due to their strong signaling patterns. Hence, attenuation of signaling strength of CD28-based CARs is considered a viable strategy for prolonging persistence. Previous work in conventional T-cells has suggested that restricting ITAM diversity to single ITAM sequences while maintaining same ITAM number can attenuate signaling strength to different extents. Based on this, we have designed ITAM diversity restricted CD28-based murine anti-CD19 CARs with the goals of optimizing CAR signaling strength and studying the individual signaling properties of the individual CD3ζ ITAM sequences. They are named as ζWT (conventional CD28-CD3ζ CAR), ζA, ζB and ζC CARs based on which individual CD3ζ ITAM they express in three copies. Our approach is slightly different from other ITAM related design manipulations where ITAM number has been reduced. We hypothesize that the individual CD3ζ ITAMs will exhibit non-redundant signaling properties in the diversity restricted CARs which will allow for optimization of CAR signaling and improve CAR T-cell persistence and function. To test this, we first interrogated the signaling differences of the individual CD3ζ ITAMs using western blots and Ca2+ signaling by flow cytometry in CAR T-cells stimulated with CD19+ beads or tumor cells. Our observations suggest ζB and ζC CARs have a lower signaling strength compared to ζWT and ζA. To understand how the signaling differences affect CAR-T function, we performed in vitro CAR-T:CD19+ tumor cell co-culture functional assays to analyze their specific cytotoxicity, degranulation and cytokine expression profiles. We observed ζB and ζC CAR-Ts have a weaker activation profile based on the CD107a degranulation assay and their cytokine expression profile. To follow this up, we performed an in vitro seven-day exhaustion assay with repeat stimulation using CD19+ beads to analyze their propensity for exhaustion. Again, ζB and ζC CAR-Ts had lower expression of exhaustion related inhibitory receptors suggesting they are less prone to exhaustion. In conclusion, we observe individual CD3ζ ITAM sequences have non-redundant signaling properties in terms of signaling strength. ζB and ζC CAR-Ts which have lower signaling strength have a weaker activation profile and are less prone to exhaustion. Based on these observations, we predict ζB and ζC will perform better long-term in vivo and provide better protection against tumor growth. Citation Format: Shubhabrata Majumdar, Hilda Echelibe, Matthew L. Bettini. CD3ζ ITAM diversity determines chimeric antigen receptor signaling and function [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B043.

Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

A Chimera Antigen Receptor Containing TLR4 Signaling Domain Enhances CAR-iMACs Polarization and Potency against Solid Tumors

Harnessing CD3 diversity to optimize CAR T cells

Utilizing distinct CAR and TCR signaling to generate enhanced cellular immunotherapy

A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects

Abstract B043: CD3ζ ITAM diversity determines chimeric antigen receptor signaling and function

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2<SUP>nd</SUP> Generation Chimeric Antigen Receptor-Modified T Cells

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells

CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells

Co-Stimulatory Receptor Signaling in CAR-T Cells

CD27 agonism coordinates with CD28 and 4-1BB signal to augment the efficacy of CAR-T cells in colorectal tumor

Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells

CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis

Use of IL-3RB to mediate antitumor effect of CAR-T cells through the JAK-STAT signaling pathway.

Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screening and single-cell sequencing

Chimeric Antigen Receptor-T Cells With 4-1bb Co-Stimulatory Domain Present A Superior Treatment Outcome Than Those With Cd28 Domain Based On Bioinformatics

Exploiting T cell signaling to optimize engineered T cell therapies

Incorporation Of 4-1bb Endowed The Potent Cd33 Specific Chimeric Antigen Receptor T Cells With Anti-Exhaustion Capacity And Increased Central Memory Compartment

Differential protein-protein interactions underlie signaling mediated by the TCR and a 4-1BB domain–containing CAR